- Home
- PZZA vs SVRA Comparison
PZZA vs SVRA Comparison
Compare PZZA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PZZA | SVRA |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1995 | 2009 |
Fundamental Metrics
Financial Performance| Metric | PZZA | SVRA |
|---|---|---|
| Price | $35.37 | $5.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $45.00 | $7.33 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $2,068,421,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | $39.28 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $30.16 | $1.89 |
| 52 Week High | $55.74 | $7.01 |
Technical Indicators
Market Signals| Indicator | PZZA | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 64.04 |
| Support Level | $30.47 | $5.86 |
| Resistance Level | $40.14 | $6.10 |
| Average True Range (ATR) | 1.46 | 0.28 |
| MACD | 0.22 | 0.10 |
| Stochastic Oscillator | 85.54 | 89.37 |
Price Performance
Historical ComparisonAbout PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).